Cargando…

Sensitivity of brain MRI and neurological examination for detection of upper motor neurone degeneration in amyotrophic lateral sclerosis

OBJECTIVES: To investigate sensitivity of brain MRI and neurological examination for detection of upper motor neuron (UMN) degeneration in patients with amyotrophic lateral sclerosis (ALS). METHODS: We studied 192 patients with ALS and 314 controls longitudinally. All patients visited our centre twi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nitert, Abram D, Tan, Harold HG, Walhout, Renée, Knijnenburg, Nienke L, van Es, Michael A, Veldink, Jan H, Hendrikse, Jeroen, Westeneng, Henk-Jan, van den Berg, Leonard H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Neurodegeneration
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685620/ https://www.ncbi.nlm.nih.gov/pubmed/34663622 http://dx.doi.org/10.1136/jnnp-2021-327269

Ejemplares similares

Widespread structural brain involvement in ALS is not limited to the C9orf72 repeat expansion
por: Westeneng, Henk-Jan, et al.
Publicado: (2016)

UNC13A in amyotrophic lateral sclerosis: from genetic association to therapeutic target
por: Willemse, Sean W, et al.
Publicado: (2023)

Multimodal longitudinal study of structural brain involvement in amyotrophic lateral sclerosis
por: van der Burgh, Hannelore K., et al.
Publicado: (2020)

Imaging the pathoanatomy of amyotrophic lateral sclerosis in vivo: targeting a propagation-based biological marker
por: Kassubek, Jan, et al.
Publicado: (2018)

Retrotransposons in the development and progression of amyotrophic lateral sclerosis
por: Savage, Abigail L, et al.
Publicado: (2019)

Flavour identification in frontotemporal lobar degeneration
por: Omar, Rohani, et al.
Publicado: (2013)

Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosis
por: Turner, Martin R, et al.
Publicado: (2016)

Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights
por: Vucic, Steve, et al.
Publicado: (2013)

Cognition and behaviour in frontotemporal dementia with and without amyotrophic lateral sclerosis
por: Saxon, Jennifer A, et al.
Publicado: (2020)

Value of systematic genetic screening of patients with amyotrophic lateral sclerosis
por: Shepheard, Stephanie R, et al.
Publicado: (2021)

Validation of the new consensus criteria for the diagnosis of corticobasal degeneration
por: Alexander, S K, et al.
Publicado: (2014)

Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study
por: Lu, Ching-Hua, et al.
Publicado: (2015)

The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey
por: Turner, Martin R, et al.
Publicado: (2015)

Increased functional connectivity common to symptomatic amyotrophic lateral sclerosis and those at genetic risk
por: Menke, Ricarda A L, et al.
Publicado: (2016)

Can regional spreading of amyotrophic lateral sclerosis motor symptoms be explained by prion-like propagation?
por: Kanouchi, Tadashi, et al.
Publicado: (2012)

TDP-43 proteinopathies: a new wave of neurodegenerative diseases
por: de Boer, Eva Maria Johanna, et al.
Publicado: (2021)

Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management
por: O'Brien, John, et al.
Publicado: (2020)

Predicting loss of independence and mortality in frontotemporal lobar degeneration syndromes
por: Murley, Alexander G, et al.
Publicado: (2021)

Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias
por: Mehta, Puja R, et al.
Publicado: (2019)

Higher blood high density lipoprotein and apolipoprotein A1 levels are associated with reduced risk of developing amyotrophic lateral sclerosis
por: Thompson, Alexander G, et al.
Publicado: (2022)

Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis
por: Wilson, Katherine M, et al.
Publicado: (2022)

Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis
por: Kmetzsch, Virgilio, et al.
Publicado: (2021)

Plasma inflammation for predicting phenotypic conversion and clinical progression of autosomal dominant frontotemporal lobar degeneration
por: Asken, Breton M, et al.
Publicado: (2023)

Neurite orientation and dispersion density imaging (NODDI) detects cortical and corticospinal tract degeneration in ALS
por: Broad, Rebecca J, et al.
Publicado: (2019)

Hypermetabolism in ALS is associated with greater functional decline and shorter survival
por: Steyn, Frederik J, et al.
Publicado: (2018)

Primary lateral sclerosis: consensus diagnostic criteria
por: Turner, Martin R, et al.
Publicado: (2020)

Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia
por: Meeter, Lieke H H, et al.
Publicado: (2019)

Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions
por: van der Ende, Emma L., et al.
Publicado: (2021)

Prognostic biomarkers in prodromal α-synucleinopathies: DAT binding and REM sleep without atonia
por: Kunz, Dieter, et al.
Publicado: (2023)

Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia
por: Panman, Jessica L, et al.
Publicado: (2021)

CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease
por: Teuber-Hanselmann, Sarah, et al.
Publicado: (2020)

Serum neuronal exosomes predict and differentiate Parkinson’s disease from atypical parkinsonism
por: Jiang, Cheng, et al.
Publicado: (2020)

Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
por: van der Ende, Emma L, et al.
Publicado: (2020)

Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s disease
por: Singleton, Ellen, et al.
Publicado: (2021)

Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans
por: Maccecchini, Maria L, et al.
Publicado: (2012)

Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS
por: Gregory, Jenna M, et al.
Publicado: (2020)

Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression
por: Thompson, Andrew Geoffrey Bourne, et al.
Publicado: (2018)

MRI Clustering Reveals Three ALS Subtypes With Unique Neurodegeneration Patterns
por: Tan, Harold H. G., et al.
Publicado: (2022)

The Distinct Traits of the UNC13A Polymorphism in Amyotrophic Lateral Sclerosis
por: Tan, Harold H. G., et al.
Publicado: (2020)

ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials
por: Wang, Jinping, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ec5e8iiletq0mum1d576gd49oa